Innovation Cube Ascends to CIIE Summit: Roche Unveils New Blueprint for a Healthier Future

ShanghaiOctober 31, 2022PR Newswire -- The 5th China International Import Expo (hereinafter referred to as "CIIE") will be held in Shanghai from November 5th to 10th. Roche Pharmaceuticals, together with Roche Diagnostics, will attend the CIIE for the fifth time. At this year's CIIE, as one of the largest exhibitors in the Medical Devices and Healthcare Products exhibition area, Roche will present a visual feast on its 1,000-square-meter booth under the theme of "Innovate Together, Lead the Future." On this year’s Roche booth, the "Innovation Cube" aggregates layer by layer and rises continuously, embodying the innovative spirit of Roche over its century-long history. It symbolizes the collaboration between Roche's diagnostics and pharmaceuticals divisions, exploring and creating infinite possibilities with ecosystem partners to safeguard the future of human health. Meanwhile, Roche will showcase its strongest-ever lineup at an exhibition, including nearly 30 marketed and soon-to-be-launched products across its entire portfolio, globally launched products, and innovative solutions. With concerted efforts, Roche aims to accelerate innovation in China’s healthcare sector and write a new blueprint for a healthy future.

"The CIIE has become an excellent platform for the launch and gathering of global innovative products and cutting-edge technologies, as well as a bridge for communication between governments and enterprises, and among enterprises themselves. The timely convening of the 5th CIIE will release more 'Chinese opportunities' to the world, further strengthening Roche's confidence and commitment to long-term investment and deep-rooted development in China. Over the past three years, Roche Pharmaceuticals has invested over 1.4 billion USD, further increasing its commitment to the Chinese market," said Ms. Bian Xin, General Manager of Roche Pharmaceuticals China. "This year, under the theme of 'Gathering Strength for Innovation, Leading the Future,' Roche will attend the CIIE for the fifth time. While bringing more globally innovative products and solutions, we look forward to leveraging this open and communicative platform of the CIIE to collaborate with multiple partners. Together, we will focus on exploring innovative healthcare solutions, jointly building, creating, and sharing a localized healthcare ecosystem, and contributing to the early realization of the Healthy China 2030 goals."

Gathering Global Innovative Products and MorePublish, benefiting more patients in China

Over the past five years, the CIIE has become an excellent launching and gathering platform for global innovative products and cutting-edge technologies, fully unleashing the powerful spillover effects of the CIIE. At the CIIE, Roche showcased over 30 innovative products and new indications, nearly half of which have already entered China, benefiting Chinese patients. This year, Roche will present at the CIIE with a full product portfolio of nearly 30 products that are already on the market or about to be launched, as well as globally first-launched products and innovative solutions. Among them, in addition to several products already launched in China,Product, as well as nearly 10 global innovative products that are about to enter the Chinese market, covering major disease areas such as hematology, breast cancer, ophthalmology, and neuroscience. At the same time, Roche will leverage the platform of the CIIE to continue collaborating with partners from across the industry, government, academia, and research, jointly promoting the innovative development of China's healthcare sector.

As a leader in the field of hematology, Roche has a rich pipeline of blood products. This time, several products that are about to be launched in China will be introduced.New ProductAmong them, Polivy (generic name: Polatuzumab Vedotin), the world’s first ADC (antibody-drug conjugate) targeting CD79b, has shown experimental data surpassing the gold standard of first-line treatment for over 20 years, and is expected to revolutionize the treatment landscape for diffuse large B-cell lymphoma (DLBCL). Another innovative drug in the field of rare hematological diseases, Crovalimab (trade name: Piaoshengkai), is expected to become the first innovative drug to be launched in China ahead of Europe and the United States, filling the treatment gap for Chinese patients with paroxysmal nocturnal hemoglobinuria (PNH). In the field of breast cancer, Roche will introduce Phesgo, the world’s first combination formulation of subcutaneous injection for HER2-positive breast cancer, which is about to be launched in China. It can be administered through a single 5-8 minute subcutaneous injection, significantly shortening the administration time and providing patients with a faster and less invasive new treatment option. Roche has always been committed to exploring groundbreaking therapies in ophthalmology, and at this CIIE, it will present Faricimab, the world’s first bispecific antibody in the ophthalmology field. It has already been approved for marketing in Europe and the United States and is considered the first treatment option with a novel mechanism of action in the ophthalmology field in more than a decade.

At this year's CIIE, in addition to showcasing global innovative products and cutting-edge technologies, Roche will also bring multiple sessions.Press ConferenceA plethora of breakthrough innovations are showcased on the CIIE stage, covering major disease areas such as hematology, breast cancer, lung cancer, neuroscience, and broad-spectrum anti-tumor treatments, benefiting a wide range of patients in China. At the same time, leveraging the bridging effect of the CIIE, Roche, together with member companies of Roche Accelerator China, will make a collective appearance to jointly contribute to the construction of a local medical innovation ecosystem and promote Chinese innovation going global.

In the future, Roche will continue to leverage the momentum of the CIIE to further invest in China. While accelerating the availability of cutting-edge innovations to benefit Chinese patients more quickly, Roche will actively collaborate with various partners, including the government, medical institutions, and non-governmental organizations. Through a series of impactful and sustainable initiatives, Roche is committed to creating a healthier and brighter future for patients in China.